coronavirus vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, according to preliminary trial results.While the early to mid-stage trials were not designed to assess the efficacy of CoronaVac, researchers said it could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies with macaques.
The global race for coronavirus vaccine doses: how does Canada compare? The study comes hot on the heels of upbeat news this month from U.S.